Losartan Potassium/Amlodipine Camsylate/Ezetimibe/Rosuvastatin Calcium

Tier C — Watch / trade

Hanmi Pharmaceutical Co., Ltd.

Originator

2020

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：AT1, VDCCs, NPC1L1, HMGCR

Brand：Amosartan XQ

Indications (approved)：Hypertension, Dyslipidaemia

Regional status

China

Japan

Factories producing this API12

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

12 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Losartan Potassium/Amlodipine Camsylate/Ezetimibe/Rosuvastatin Calcium?

Approved indications include: Hypertension, Dyslipidaemia.

When does the Losartan Potassium/Amlodipine Camsylate/Ezetimibe/Rosuvastatin Calcium patent expire?

No public expiry year is available for Losartan Potassium/Amlodipine Camsylate/Ezetimibe/Rosuvastatin Calcium yet; this page updates once verified.

How do I get a quote for Losartan Potassium/Amlodipine Camsylate/Ezetimibe/Rosuvastatin Calcium intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27